Clinical trial · Observational
Men Undergoing Radical Prostatectomy
Serum Protein Profiling to Characterize Patient Risk in Men Undergoing Radical Prostatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if the protein pattern in your blood can predict whether or not your prostate tumor is aggressive. We will use a new and very sensitive technique, called mass spectroscopy, to measure hundreds of pieces of protein in your blood. A computer will make a picture of the protein pattern. We will do this in 500 men before their prostate surgery and see if there is a pattern that predicts what the tumor looks like under the microscope. We will also check the protein pattern in your blood 6 weeks to 12 months after the surgery to see if your pattern changes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole Blood Draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1 men with prostate cancer
- description
- Patients who have opted for radical prostatectomy as treatment for prostate cancer.
- interventionNames
- Other: Whole Blood Draw
Primary outcomes (1)
- measure
- To determine if men with pathologically latent prostate cancer have a different preoperative proteomic profile than men with a pathologically significant cancer.
- timeFrame
- conclusion of study
Secondary outcomes (4)
- measure
- To determine the effect of radical prostatectomy on the proteomic profile in blood samples from men with a pathologically latent cancer. This should suggest the contribution of 'benign'prostate to the small peptide proteomic profile in blood.
- timeFrame
- conclusion of study
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men aged 18 years or older with clinically localized prostate cancer (cT1- T2NxM0) * Scheduled for radical prostatectomy * Prostate biopsy at least 6 weeks prior to scheduled radical prostatectomy * Signed, informed consent * Patient must be able to attend both the preoperative and postoperative blood draws. Exclusion Criteria: * A period of less than 6 months prior/current treatment with hormonal therapy (LHRH agonist/antagonist, antiandrogen, 5-alpha-reductase inhibitor). * A period of less than 6 months prior/current treatment with an alpha-blocker
References
Publications (0)
Data not yet available